FMIBlog's blog

The global medical bed market demand is projected to surpass US$ 3,611.9 million in 2023 and is likely to attain a valuation of US$ 5,469.0 million by 2033. The medical bed market share is expected to rise at a CAGR of 4.2% from 2023 to 2033.

Environmental sustainability is becoming increasingly crucial in the healthcare sector. Manufacturers of medical beds are researching eco-friendly materials and sustainable design approaches. Hospitals and healthcare institutions are progressively looking for beds with a lower environmental effect aligned with larger sustainability aims.

Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-15013

Hybrid beds are likely to become common in the coming years. Hybrid medical beds combine classic characteristics with cutting-edge innovations such as built-in patient lifts. These beds are intended to make patient transfers within healthcare institutions more efficient. Hybrid beds improve safety and efficiency in healthcare settings by decreasing physical strain on both patients and caregivers during transfers.

In the global medical bed industry size, predictive maintenance is highly valued. Predictive maintenance system continuously analyzes the status of medical bed components. The technology can forecast when maintenance or repairs are required by evaluating sensor data. This proactive strategy cuts down on bed downtime, protects patient safety, and decreases disruptions in healthcare delivery.

Medical beds with biohazard precautions are being created in response to health catastrophes such as pandemics. Containment curtains and negative pressure devices are included in these beds to safeguard healthcare personnel and limit the spread of infectious illnesses. They give an extra layer of security in high-risk healthcare settings.

"Sustainability is paramount, with eco-friendly materials and designs becoming the norm. Regional firms are taking against global behemoths, and collaborations with healthcare institutions are pushing personalization. This surge indicates a future in which medical beds improve patient care and correspond with a more sustainable and patient-centered healthcare landscape,” says an FMI analyst.

Key Takeaways from the Medical Bed Market Report:

  • In 2018, the global market size stood at US$ 2,998.6 million.
  • The market size expanded at a 3.6% CAGR from 2018 to 2022.
  • In 2022, the global market size stood at US$ 3,482.6 million.
  • The intensive care application segment will thrive at a 4.4% CAGR through 2033.
  • The electric beds segment will flourish at a 4.8% CAGR through 2033.
  • The medical bed market in the United States will rise at a 3.8% CAGR through 2033.
  • The medical bed market in India will thrive at a 5.4% CAGR through 2033.
  • The medical bed market in China will flourish at a 6.1% CAGR through 2033.

Competitive Landscape:

The medical bed market is undergoing a tremendous revolution, which is being driven by innovation, sustainability, and cooperation. Through IoT and AI, leading manufacturers are transforming hospital beds into smart, networked care hubs.

Manufacturers need to constantly enhance the features and functionality of beds to make them more accessible and inexpensive to healthcare practitioners. Moreover, emerging markets in Asia, Latin America, and Africa are expected to offer significant growth potential. The need for medical beds will grow as these regions' healthcare infrastructure improves and their populations age.

Recent Developments Observed by FMI:

  • In March 2023, the Middle East opened a prominent hospital in  Tehran. The Mahdi Clinic Hospital includes 1,000 beds.
  • Godrej & Boyce debuted Acura, a line of hospital beds, in January 2021 through its business subsidiary Godrej Interio.

Key Companies in the Medical Bed Market:

  • Hill-Rom Holdings, Inc.
  • Invacare Corporation
  • Drive Medical
  • Stryker Corporation
  • ArjoHuntleigh
  • Gendron Inc
  • Graham Field Health Products, Inc.
  • Hard Manufacturing Co
  • Umano Medical
  • Transfer Master
  • American Medical Equipment (AME)
  • ProBed Medical
  • Getinge AB
  • Paramount Bed Holdings
  • Joerns Healthcare LLC
  • Narang Medical

Medical Bed Market Segmentation:

By Product:

  • Acute Care Beds
  • Long-term Care Beds
  • Psychiatric Care Beds
  • Maternity Beds
  • Others

By Bed Type:

  • Manual Beds
  • Electric Beds
  • Semi-electric Beds

By Usage:

  • Intensive Care
  • Non-intensive Care

By End-user:

  • Hospitals
  • Home Care Settings
  • Rehabilitation Centers
  • Others

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific (APAC)
  • The Middle East & Africa (MEA)
  • Japan

The global patient positioning system market size is projected to reach US$ 508.4 million by 2024. The patient positioning system sales are expected to witness a robust CAGR of 5.4% from 2024 to 2034. By 2034, the demand for the patient positioning system is anticipated to reach a valuation of US$ 857.4 million.

Cancer's rising incidence and developing economies' rapidly expanding healthcare industries are set to be significant factors propelling the patient positioning system industry. The primary trend contributing to the sales of patient positioning systems during the projected period is the aging population and the rising incidence of cancer.

Get Your Report Sample To Gain Comprehensive Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-15012

Market Catalysts Powering the Patient Positioning System Sector:

An aging population, a rise in the frequency of chronic diseases, and an increase in the demand for minimally invasive surgeries are stimulating the patient positioning system industry. The need for accurate patient positioning to improve treatment outcomes and the development of medical imaging technologies propel patient positioning system market expansion.

The rising adoption of patient positioning systems is attributed to healthcare facilities' emphasis on improving patient comfort, guaranteeing safety during procedures, and streamlining workflow efficiency. These variables work together to support continuous innovation in creating contemporary patient positioning solutions and strengthen the patient positioning techniques market.

Deterrents Affecting the Patient Positioning Device Market Evolution:

End-users' lack of awareness, healthcare facilities' budgetary restrictions, and the market's high initial costs pose difficulties. Regulatory complexities and compliance issues constrain patient positioning system market expansion.

Broad acceptance is impeded by the absence of uniform guidelines for patient positioning systems during various medical procedures. Worries about the prospect of infections, ergonomic issues, and the requirement of specialized training escalate roadblocks in the patient positioning technology market.

Regional Dynamics of Patient Positioning System Market:

  • North America leads the patient positioning device market due to its advanced medical technology adoption rate and robust healthcare infrastructure.
  • The demand for patient positioning solutions continues to rise in the region due to increased surgical procedures and an emphasis on bettering patient outcomes.
  • Due to the existence of reputable healthcare facilities and rising investments in medical innovations, Europe has seen steady market growth for patient positioning systems.
  • Europe is consistently committed to improving the effectiveness and safety of medical procedures, as evidenced by the increasing adoption of ergonomic patient positioning solutions.
  • As chronic diseases become prevalent and the healthcare system improves, the Asia Pacific patient positioning system market develops swiftly.
  • Growth in hospitals and rising knowledge of sophisticated patient positioning techniques advance the considerable market growth in Asia Pacific.

“The increasing emphasis on precision in medical procedures contributes to a surge in demand for patient positioning systems in the dynamic field. Technological advancements and the development of healthcare infrastructure foster improved patient outcomes and innovation, which stimulates patient positioning system market expansion.”, says an analyst at FMI

Key Takeaways:

  • The air pump assisted positioning systems segment in the product type category to grab a share of 40.7% from 2024 to 2034.
  • In the end-user category, the hospital segment to acquire a market share of 28.3% between 2024 and 2034.
  • The United States diagnostic imaging positioning device market is anticipated to surge at a CAGR of 2.4% through 2034.
  • Germany patient positioning system market to develop at a CAGR of 3.2% by 2034.
  • The surgical positioning market growth in the United Kingdom to witness a CAGR of 3.5% from 2024 to 2034.
  • China patient alignment system market is expected to surge at a CAGR of 7.0% until 2034.
  • India patient positioning device market is anticipated to boost at a CAGR of 8.0% from 2024 to 2034.

Competitive Landscape:

Healthy competition in the market is driven by increased product launches, a rise in surgical procedures, an expanding healthcare infrastructure, and strategic partnerships between significant patient positioning system vendors. The diverse market growth trajectory of patient positioning system manufacturers to spur innovation, increase accessibility to leading-edge medical technologies, and improve patient outcomes and care.

Recent Developments:

  • A deal to acquire Medline Industries for over US$ 30 billion was reached in June 2021 by Blackstone, Hellman & Friedman, and Carlyle. Without considering borrowings, the transaction would be valued at US$ 34 billion and more than US$ 30 billion.
  • Global MedTech leader Baxter International Inc. declared in September 2021 that it had successfully acquired Hillrom. At US$ 10.5 billion, Baxter paid US$ 156 in cash for each outstanding share of Hillrom common stock. The transaction had a US$12.5 billion value.
  • Hillrom is the first company to launch a movable surgical table in July 2020. Yellofins Apex stirrups are a recent addition to the Yellofins stirrup collection, and Hillrom announced the commercial release of the PST 500, a precision surgical table.

Essential Patient Positioning System Manufacturers:

  • Medtronic plc
  • Hill-Rom Holdings Inc.
  • Stryker Corporation
  • Medline Industries
  • LP
  • Skytron, LLC

Key Segments:

By Product:

  • Tables
  • Surgical Tables
  • Air Pump Assisted Positioning Systems
  • Radiolucent Imaging Tables
  • Examination Tables
  • Patient Positioning System in Accessories

By Application:

  • Surgeries
  • Disease Diagnosis
  • Cancer Therapy

By End User:

  • Hospitals
  • Ambulatory Surgery Centers
  • Diagnostic Laboratories

By Region:

  • North America
  • Europe
  • Asia Pacific
  • The Middle East and Africa
  • Latin America

The global distance health technology market size is expected to rise at a CAGR of 16.3% in the forecast period 2024 to 2034. The market is anticipated to reach a valuation of around US$ 149.3 billion by 2034. It is expected to attain a value of US$ 33.7 billion in 2024. The market for distance health technology stood at US$ 28.5 billion in 2023.

The distance health technology market has witnessed significant growth and adoption, driven by several factors, including technological advancements, changing healthcare delivery models, and the need for accessible and efficient healthcare services. Healthcare professionals have increasingly adopted this technology to enhance patient care, improve access to medical services, and streamline healthcare delivery.

Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-8413

Key distance health technology providers are actively developing and deploying innovative solutions. These manufacturers produce telemedicine carts, remote monitoring devices, digital health platforms, and other essential hardware & software components. 

The market reflects a growing acceptance and integration of distance health technology supported by healthcare professionals, key manufacturers, and government initiatives. This trend is expected to continue as technology advances, addressing healthcare challenges and improving the accessibility and quality of healthcare services globally.

Key Takeaways from the Market Study:

  • By application, teleconsultation held the leading share of 28.7% in terms of value in 2023.
  • The United States is projected to expand at a CAGR of 13.8% by 2034.
  • China is expected to lead the market based on country, expanding at a CAGR of 16.8% by 2034.
  • The global market is expected to surge at a CAGR of 16.3% by 2034.
  • In terms of products, telemedicine hardware is anticipated to rise at a 13.3% CAGR by 2034.

"Robust healthcare infrastructure, technological advancements, and a high level of awareness among healthcare professionals & the general population would support the market. Throughout the projection period, the widespread use of smartphones and other similar devices, along with the internet's quick expansion, will drive the market for distant health technologies," says a lead analyst of Future Market Insights.

Competitive Landscape:

Acquisition and partnership among leading companies or brands are the key growth strategies of manufacturers such as Tryten Technologies, Honeywell International, Inc., Cisco Systems, Inc., and Axis Communications. They aim to enhance their presence in the market and compete with other players. Following are a handful of examples of acquisitions made by them to be at the top position: 

  • In January 2023, Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals and pharmacy providers, acquired Tryten Technologies Inc., a lightweight, easy-to-maneuver mobile cart solutions designer.
  • In Oct 2023, Sound Intelligence and Axis Communications announced the development of a new solution for healthcare and beyond through their partnership.

 

Key Companies Profiled:

  • VSee
  • Omcare
  • Teladoc Health, Inc.
  • Health Recovery Solutions
  • Cloud DX
  • AMD Global Telemedicine
  • Tech4Life Enterprises
  • TytoCare Ltd.
  • MEDWAND SOLUTIONS, INC.
  • Tryten Technologies, Inc.
  • Honeywell International, Inc.
  • Cisco Systems, Inc.
  • Rudolf Riester GmbH

Distance Health Technology Market Segmentation by Category:

By Product:

  • Telemedicine Hardware
    • Telemedicine Carts
      • Single Display
      • Dual Display
    • Telemedicine Kiosks
      • Portable
      • Fixed
    • Medical Devices
      • Telemedicine Kits
      • Remote Patient Monitoring Devices
        • Remote Vital Monitors
        • Blood Pressure Devices
        • Bluetooth Enabled Scales
        • Digital Thermometers
        • Blood Glucose Meters
        • Pulse Oximeters
        • Ekg Monitors
        • Electronic Pills
        • Acoustic Monitoring Systems
      • Other Portable Telemedicine Devices
    • Digital Camera
  • Telemedicine Software
    • Cloud-based
    • On-premises

By Application:

  • Teleconsultation
  • Teleneurology
    • Epilepsy
    • Alzheimer
    • Early Dementia
    • Other Teleneurology Services
  • Telehealth in Disability
  • Tele-physical Therapy
  • Remote Diet and Nutrition Counseling
  • Telehealth Urgent Care
  • Telepharmacy Services
  • Telepsychiatry
  • Remote Care Services
  • Acoustic Monitoring
  • Others

By End-user:

  • Hospitals
  • Clinics
  • Specialty Centers
  • Long Term Care Centers
    • Nursing Home
    • Homecare Settings
    • Others Settings
  • Clinical Pharmacy Services

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

The global perfusion imaging market is slated to create a revenue of almost US$ 2,421.4 million in 2024 owing to its rising importance in healthcare facilities. As per FMI, the perfusion imaging market is set to surge at a CAGR of 3.4% from 2024 to 2034. The net worth of the perfusion imaging industry is estimated at almost US$ 3,382.8 million by 2034 following this fair growth rate.

Rising prevalence of myocardial infarction and ischemic heart disease has increased the need for perfusion imaging equipment in the medical field. Along with that, a growing inclination toward non-invasive diagnostic methods has boosted its adoption in modern healthcare facilities as well as clinics.

Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-9650

Key Takeaways from the Perfusion Imaging Market Study Report:

  • The United States is witnessing a comparatively slow growth rate of 1.9% due to market saturation that is estimated to continue till 2034.
  • Germany holds a significant share of the European diagnostic imaging market and is penned in to advance at 2.5% CAGR between 2024 and 2034.
  • In Asia, India is currently creating a noticeable demand for perfusion scanners resulting in an estimated CAGR of 5.0% for the projected years.
  • Thailand is another steadily growing market with an estimated CAGR of 3.5% from 2024 to 2034.

Competitive Landscape for the Perfusion Imaging Market Players:

The overall market is diversifying slowly with government support in emerging economies to their regional players. Better image resolution, speed, and accuracy of perfusion imaging solutions from leading market players are becoming more useful for diagnosing and tracking a wide range of medical disorders. Meanwhile, emerging market players are resorting to collaborations and mergers with big players to gain technical advantage in their respective regions.

“Prevalence of neurological and cardiovascular illnesses, particularly in the United States and Europe, has resulted in a highly developed healthcare system for adoption of perfusion scanning equipment and technologies. However, swift developing economies such as India, China, and South Korea are strengthening their healthcare infrastructure favoring the regional diagnostic imaging market in Asia,” – says a lead analyst at FMI.

Recent Developments by the Perfusion Imaging Industry Participants:

  • In November 2023, Brainomix, based in the United States, announced the release of its entire suite of FDA-cleared components in its Brainomix 360 platform which is an integrated stroke imaging solution. The firm had previously announced an FDA-cleared e-ASPECTS component which presents a platform designed to help doctors make imaging-based treatment decisions at all stages of the stroke pathway. The Brainomix 360 e-ASPECTS smartphone app is also an FDA-cleared decision support tool for evaluating stroke symptoms on plain CT brain imaging.
  • In March 2024, Lantheus Holdings Incorporated, based in the United States, announced that the Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) for DEFINITY® (Perflutren Lipid Microsphere). It can be used as an ultrasound-enhancing agent for use in pediatric patients with suboptimal echocardiograms. This clearance marks a significant advancement in pediatric medicine and DEFINITY boasts of being the most widely used, well-researched, and reliable diagnostic ultrasound-enhancing agent in the country.

Key Players Profiled in the Perfusion Imaging Market Report:

  • GE Healthcare
  • Toshiba Medical System.
  • Positron
  • Aetna Inc.
  • NeuSoft
  • Bracco
  • Cigna
  • Kmhlabs
  • Perimed AB.
  • Siemens Health
  • Philips Healthcare
  • Lantheus Medical Cardiac Imaging Solutions Inc.

Key Segments Covered by Perfusion Imaging Industry Survey Report:

By Modality Type:

  • Single Photon Emission Computed Tomography (SPECT)
  • Positron Emission Tomography (PET)
  • Magnetic Resonance Imaging (MRI)
  • Computed tomography (CT)
  • Doppler echocardiography

By Application:

  • Coronary artery disease (CAD)
  • Myocardial infarction (MI)
  • Cardiomyopathy
  • Epilepsy
  • Dementia
  • Transplant evaluation
  • Brain Trauma
  • Pulmonary embolism (PE)
  • Osteonecrosis
  • Other Applications

By End User Verticals:

  • Hospitals
  • Ambulatory Surgery Center
  • Diagnostic Imaging Centers
  • Other End Users

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia and Pacific
  • Middle East and Africa (MEA)

The global closed system transfer devices market demand has marked a significant milestone, estimating a staggering US$ 872 Million valuation in 2022. This achievement follows a trajectory of unprecedented growth, anticipated to soar to an impressive US$ 3800 Million by 2032. The industry's evolution, propelled by cutting-edge technological advancements, promises revolutionary changes in healthcare service delivery.

The forecast, as projected by FMI, outlines a remarkable compound annual growth rate (CAGR) of 18.1% during the ten-year period from 2022 to 2032. This unprecedented growth signifies not just a burgeoning market, but a transformation in the way healthcare is administered and managed globally.

Discover Our Expert Analysis with Our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-9654

"The rapid expansion of the closed system transfer devices market is a testament to the relentless pursuit of innovation and the commitment to enhancing healthcare services worldwide," stated Future Market Insights. "Technological advancements play a pivotal role in redefining the landscape of healthcare delivery, ensuring safer and more effective patient care."

Closed system transfer devices have emerged as a critical component in the healthcare industry, facilitating the secure transfer of medications and reducing the risk of contamination or exposure for both healthcare workers and patients. The market's exponential growth reflects the increasing adoption of these devices across healthcare facilities globally.

This meteoric rise aligns with the market's ever-evolving demands for heightened safety protocols and the imperative need for more efficient healthcare delivery systems. The surge in investments and support from various sectors augurs well for the continued advancements within the closed system transfer devices industry.

As the market continues its upward trajectory, stakeholders, innovators, and healthcare providers remain committed to fostering a safer, more secure healthcare environment, ensuring the best possible outcomes for patients and healthcare professionals alike.

Key Takeaways from the Market Study: Closed System Transfer Devices:

  • Growing Demand: The closed system transfer devices (CSTD) market is witnessing significant growth due to increasing concerns about the safety of healthcare workers and patients during the handling of hazardous drugs. The demand for CSTDs is rising as they provide a closed environment for drug transfer, minimizing the risk of contamination and exposure.
  • Stringent Regulatory Standards: Regulatory bodies and organizations such as the US Food and Drug Administration (FDA) and Occupational Safety and Health Administration (OSHA) have issued guidelines and standards regarding the safe handling of hazardous drugs. Compliance with these standards is driving the adoption of closed system transfer devices across healthcare facilities and pharmacies.
  • Increased Awareness: There is a growing awareness among healthcare professionals about the potential risks associated with the handling of hazardous drugs. This awareness has led to a higher demand for closed system transfer devices as healthcare facilities prioritize the safety of their staff and patients.
  • Oncology Segment Dominates: The oncology segment holds a significant share in the closed system transfer devices market. Chemotherapy drugs are highly hazardous, and their safe handling is crucial. CSTDs are extensively used in oncology units and cancer treatment centers to minimize the risk of exposure to these drugs.
  • Hospital Settings Lead Adoption: Hospitals are the major end-users of closed system transfer devices due to the large number of drug handling activities performed within their premises. The implementation of closed system transfer devices in hospitals ensures the safety of healthcare workers during drug preparation, administration, and disposal.

Closed System Transfer Devices Market Trends and Drivers:

The most important ones include the growing use of CSTDs to counteract the negative effects of cytotoxic and antineoplastic medications. Drugs known as antineoplastics are dangerous and frequently used in the treatment of cancer. Health care professionals who handle these medications during their production, distribution, administration (both pre- and post-administration), and disposal are at extremely high risk.

The use of CSTDs is advised by the National Institute for Occupational Safety and Health (NIOSH) in order to prevent the negative effects brought on by exposure to dangerous compounds that enter the body during the preparation and delivery of medications. CSTDs serve as a barrier that stops contaminants from entering and from moving from the atmosphere to a sterile environment. These benefits have led to an increase in the usage of CSTDs in healthcare facilities to combat the negative effects of dangerous medications. Chemotherapy, a widely used cancer treatment, employs one or more antineoplastic medications to kill patients' aberrant cells.

To increase safety when preparing, transporting, giving out, and discarding hazardous pharmaceuticals, closed system transfer devices (CSTDs) should be used in conjunction with other safety measures such wearing gloves, gowns, masks, and vented preparation hoods. The demand for CSTDs is anticipated to rise in the approaching years due to the rising incidence of cancer and rising use of chemotherapy therapies.

Closed System Transfer Devices Market Competition:

Some of the most prominent companies in the global Closed System Transfer Devices market are ICU Medical, Inc., Equashield LLC, Becton, Simplivia Healthcare, Dickinson and Company, B. Braun Melsungen AG, Corvida Medical, Yukon Medical, Baxter International Inc., and others.

Key Segments Profiled in the Closed System Transfer Devices Market:

By Product

  • Systems
  • Needle Free Systems
  • Needle Systems
  • Component
  • Vial Adaptors
  • Syringe Adaptors
  • Tubing Sets and Accessories

By Application

  • Pharmacy
  • Nursing
  • Veterinary

By Distribution Channel

  • Direct Sales
  • Distributors

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

The global brain implants market is projected to witness significant growth, reaching a value of US$ 18 billion by 2032, with a compound annual growth rate (CAGR) of 12.3%. This surge is propelled by several factors, including the rising incidence of nervous system cancer, the expanding geriatric population in developed nations, and the integration of cutting-edge technologies to cater to individual patient needs.

According to statistics from GLOBOCAN 2020, approximately 308,102 cases of brain and nervous system cancer were reported globally in 2020. The prevalence of conditions such as trauma, malignant tumors, and congenital deformities necessitates innovative solutions, driving the demand for brain implants. These implants not only offer therapeutic interventions but also pave the way for further technological advancements and widespread adoption.

Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-15093

While the aging population remains a significant driver for brain implant deployment, there is a notable increase in the demand for such technology among children. Birth defects like craniosynostosis, often detected during infancy, underscore the importance of brain implants in pediatric care.

Advancements in regenerative medicine, coupled with technological innovations such as computer-aided design and 3D printing, have revolutionized the manufacturing process of brain implants. Patient-specific implants, crafted from a variety of materials including polymers, ceramics, and metals, can now be efficiently produced, thereby reducing manufacturing costs and enhancing accessibility.

As the global brain implants market continues to evolve, stakeholders across the healthcare sector are poised to capitalize on these opportunities, driving innovation and improving patient outcomes.

There are several factors that are propelling the demand for brain implants:

  • Rising neurological disorders: As the population ages, there's a growing need for treatment options for conditions like Parkinson's disease, epilepsy, and depression. Brain implants offer a potential long-term solution for these patients when medication proves ineffective.
  • Mental health needs: Conditions like stress and obesity-related depression are becoming more prevalent. Brain implant technologies are being explored as a possible treatment option for these conditions.
  • Technological advancements: MRI and new technologies like deep brain stimulation are making brain implant surgery more precise and effective. This is leading to more patients being considered as candidates for this type of treatment.
  • Improved mobility: Technologies like motor neuron prostheses, Brain Computer Interfaces (BCI), and micro electrode arrays are being used to help patients with mobility issues. These advancements are increasing the potential applications of brain implants.

Overall, the demand for brain implants is being driven by a combination of factors, including the growing need for treatment options for neurological and mental health conditions, along with the development of new and more sophisticated technologies.

Key Companies Profiled:

  • Abbott Laboratories
  • Medtronic PLC
  • NeuroPace Incorporation
  • Nevro Corporation
  • Aleva Neurotherapeutics SA
  • Synapse Biomedical Incorporation
  • Boston Scientific Corporation
  • Sapiens Neuro
  • Edwards Lifesciences Corporation

Brain Implants Market Segmentation:

By Product Type:

  • Deep Brain Stimulator
  • Spinal Cord Stimulator
  • Vagus Nerve Stimulator

By Application:

  • Brain Implant for Chronic Pain
  • Brain Implant for Epilepsy
  • Deep Brain Simulation for Parkinson’s Disease
  • Brain Implant for Depression
  • Brain Implant for Essential tremor
  • Brain Implant for Alzheimer’s Disease

By Region:

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

The global HIV antivirals market has experienced a significant surge, with sales reaching an impressive US$ 30.6 billion as of 2022, according to recent reports. Projections indicate a promising trajectory, with the market poised to achieve an estimated value of US$ 47.0 billion by the conclusion of 2032, reflecting a steady Compound Annual Growth Rate (CAGR) of 4.4%.

This notable growth not only highlights advancements in pharmaceutical research and development but also underscores a commitment to enhancing healthcare solutions for individuals affected by HIV/AIDS worldwide.

Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-15095

The landscape of HIV antivirals has evolved significantly, driven by groundbreaking research and development initiatives. This progress has not only improved treatment efficacy but also enhanced patient convenience and adherence to therapeutic regimens.

"As the market continues to expand, the pursuit of advanced treatment modalities and the emphasis on accessibility and inclusivity remain pivotal," states Future Market Insights. "The projected growth underscores the collective efforts towards innovation and the unwavering commitment to improve the quality of life for individuals affected by HIV."

Factors contributing to this remarkable growth include increased awareness, expanding healthcare infrastructure, and ongoing research initiatives aimed at developing more effective and accessible treatment options for HIV.

The anticipated rise in the market for HIV antivirals signifies not only economic growth but also underscores the profound impact on public health worldwide. This trajectory positions the industry to address evolving challenges and emphasizes the importance of sustained investment in research and development.

To capitalize on the rising demand for generic anti-HIV medications, major producers are focusing on providing low-cost options. For example, cheaper generic versions of Lamivudine, Abacavir, and Efavirenz are available in the US than their branded equivalents. This move is projected to generate a lucrative opportunity for producers of generic HIV antivirals to provide low- and middle-income people with access to affordable medical services.

As the global HIV antivirals market continues to expand, it not only represents economic growth but also signifies a commitment to advancing healthcare solutions and improving the quality of life for individuals affected by HIV/AIDS worldwide.

Key Takeaways from Market Study:

  • Because of their ability to increase adherence to an HIV treatment regimen, fixed-dose combinations (FDCs) owned more than 83.2% of the market value in 2021.
  • Hospital pharmacies are the dominant sales channel for HIV antivirals, accounting for over 53.4% of the market in 2021, and are expected to increase at a CAGR of 4.5% over the next decade.
  • In 2021, the United States dominated the North American HIV antivirals market, with a total market share of around 96.8%.
  • Because of the increasing number of HIV patients in the country, India is likely to lead the growth in the South Asian market.

“With increasing awareness among the people about HIV causes and symptoms, the HIV antivirals market is set witness positive growth during the forecast period. Hence, key players are developing anti-HIC drugs vaccines to increase their revenue,” says an analyst of Future Market Insights.

Market Competition:

Key Players:

  • Merck & Co., Inc.
  • Johnson & Johnson
  • Genetech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie
  • Cipla
  • Pfizer Inc.
  • Mylan N.V.

Market players are expanding the business through collaborations, and increasing involvement in clinical trials as the key strategy with instances of key companies, such as Merck and Gilead, in order to improve their reach in the market and compete with other key players in forthcoming years. For instance:

  • Merck reported positive results from two pivotal Phase 3 trials of the experimental, once-daily oral fixed-dose combination tablet of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection in October 2021.
  • Gilead announced in March 2021, in collaboration with Merck, the development and marketing of long-acting, experimental therapy combinations of Lenacapavir and Islatravir in HIV.

Key Market Segments Covered in HIV Antivirals Market Research

By Product:

  • Fixed Dose Combinations (FDCs)
  • Integrase Strand Transfer Inhibitors (INSTIs)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Entry Inhibitors – CCR5 co-receptor antagonist
  • Protease Inhibitors (PIs)
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

The global spatial mass spectrometry market is on a trajectory of unprecedented growth, set to surge from its 2022 valuation of US$ 254.8 million to a staggering US$ 1 billion by 2032. This meteoric rise, characterized by a robust Compound Annual Growth Rate (CAGR) of 15.3%, underscores the immense potential and opportunities within the sector.

The remarkable expansion of the spatial mass spectrometry market mirrors a landscape of continual technological advancements and burgeoning demand across diverse industries. Esteemed for its precision and depth of analysis, this cutting-edge analytical technique has established a pivotal niche across pharmaceuticals, environmental studies, life sciences, and beyond.

Request A Report Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-15091

Fueled by relentless innovation and an unwavering pursuit of accuracy, the industry's growth is propelled by the convergence of technological breakthroughs, research and development endeavors, and an escalating need for high-resolution spatial analysis. As a result, the sector stands at the precipice of revolutionizing scientific exploration and application across multiple domains.

Key industry players are seizing this momentum, driving research and development initiatives to unlock the full potential of spatial mass spectrometry. Through strategic partnerships, pioneering research endeavors, and investments in state-of-the-art technologies, stakeholders are not only spurring market growth but also catalyzing a paradigm shift in the role of spatial analysis in scientific discoveries.

A primary driver of the spatial mass spectrometry industry is the escalating prevalence of cancer globally. With cancer emerging as a leading cause of mortality worldwide, the demand for advanced tools in cancer research and diagnostics is on the rise. Spatial mass spectrometry emerges as a valuable asset in this endeavor, enabling the identification and characterization of tumor cells, as well as facilitating the study of cancer treatments' effects.

Additionally, the burgeoning demand for omics-based clinical trials is propelling the spatial mass spectrometry market forward. Omics, encompassing the molecular-level study of biological systems, holds immense promise in identifying biomarkers for disease diagnosis and prognosis, as well as in formulating personalized treatment strategies. Spatial mass spectrometry emerges as a robust tool in omics-based research, facilitating the quantification and identification of diverse molecules in biological samples.

Moreover, the escalating investment in the pharmaceutical industry is serving as a catalyst for spatial mass spectrometry market growth. With pharmaceutical companies increasingly investing in cutting-edge technologies to expedite drug discovery and development processes, spatial mass spectrometry emerges as a valuable asset. It facilitates drug candidate screening for activity and toxicity, alongside offering insights into drug metabolism and distribution within the body.

While the spatial mass spectrometry market is still in its nascent stages of development, it is witnessing rapid expansion driven by burgeoning demand across diverse industries, including pharmaceuticals, academia, and clinical diagnostics.

Some Of The Key Takeaways From The Report Include:

  • The spatial transcriptomics segment is expected to grow at the highest CAGR over the forecast period, owing to its increasing use in cancer research and drug development.
  • The formalin-fixed paraffin-embedded (FFPE) sample type segment is expected to account for the largest share of the market during the forecast period, due to its wide availability and ease of use.
  • North America is expected to remain the largest market for spatial mass spectrometry over the forecast period, followed by Europe and Asia Pacific.

The growth of the spatial mass spectrometry market is being driven by a number of factors, including:

  • Increasing demand for personalized medicine: spatial mass spectrometry is a valuable tool for understanding the spatial distribution of drugs and other molecules within cells and tissues. This information can be used to develop more personalized treatment plans for patients.
  • Growing prevalence of chronic diseases: The prevalence of chronic diseases such as cancer and Alzheimer's disease is increasing worldwide. spatial mass spectrometry is a valuable tool for diagnosing and monitoring these diseases.
  • Advances in technology: Technological advances are making spatial mass spectrometry systems more affordable and accessible. This is leading to increased adoption of spatial mass spectrometry in a wider range of applications.

The key players in the spatial mass spectrometry market include:

  • 10x Genomics
  • Dovetail Genomics
  • S2 Genomics Inc
  • NanoString Technologies Inc
  • Seven Bridges Genomics
  • PerkinElmer, Inc.
  • Bio-Techne
  • Danaher Corporation
  • IonPath, Inc.

Market Segments Covered In Spatial mass spectrometry Market Analysis:

By Technology:

  • Spatial Transcriptomics
  • Spatial Genomics
  • Spatial Proteomics

By Product Type:

  • Instruments
  • Consumables
  • Software

By Workflow:

  • Sample Preparation
  • Instrumental Analysis
  • Data Analysis

By Sample Type:

  • FFPE
  • Fresh Frozen

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

The global pharmaceutical excipient market is slated to have a valuation of US$ 972.9 million in 2024. The burgeoning pharmaceutical industry is playing into the hands of pharmaceutical excipient vendors. With governments especially desirous of extending healthcare services to rural and remote parts, the pharmaceutical sector, and in turn, the pharmaceutical excipient market, is benefitting.

The pharmaceutical excipient industry is slated to progress at a CAGR of 5.1% through 2034. Excipients are moving away from the non-active role they were traditionally playing. Functional and novel excipients often provide functions like changing the color of the medicine or enhancing the effect of the active ingredient. Thus, pharmaceutical excipients are getting more of the limelight and end-users are paying more attention to them.

Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-932

By the time 2034 rolls around, the pharmaceutical excipient market’s value is forecasted to hit US$ 1,600 million. Development in the biologics sector is expected to add considerable value to the market. Similarly, developments in nanotechnology are predicted to enhance market value during the forecast period.

Some factors slow down the growth of the market. The market is heavily regulated, and the launch of new products has the potential to be slow as holdups from regulatory authorities are common. As with many pharmaceutical ingredients, consumer aversion towards them, especially artificial ingredients, is a roadblock for the market.

“Use of excipients to mask the taste of bitter medicines or to provide a different color to them is anticipated to help in the market’s progress. Despite the existence of some notable drawbacks, the multi-functionality of excipients is expected to help the market to progress along nicely,” says an analyst at FMI.

Key Takeaways from the Pharmaceutical Excipient Market:

  • The pharmaceutical excipient market is expected to be US$ 9 million in size in 2024.
  • Artificial excipients rule the roost in the market. Artificial excipients are expected to account for 34.7% of the market share in 2024.  
  • Coating is the predominant technique. For 2024, coating is anticipated to account for 33.0% of the market share.
  • China is expected to be a promising country in terms of progress for the market. The country is forecasted to have a CAGR of 5.6% from 2024 to 2034 in the market.
  • The United States and Japan are poised to be lucrative countries for the market. For the forecast period, the CAGR for both the United States and Japan is predicted to be 5.3%.
  • The market is expected to progress at a CAGR of 5.4% in Germany.

Competition Analysis of the Pharmaceutical Excipient Market:

The pharmaceutical excipient market is fragmented, with small-scale companies looking at product differentiation. While bigger companies look to expand production capabilities.

Recent Developments in the Pharmaceutical Excipient Market:

  • In October 2023, Clariant Chemicals introduced three new excipients as part of its VitiPure range.
  • In November 2021, Gattefossé unveiled excipients named Labrafac MC60, Gelucire 59/14, and Emulfree Duo.

Key Companies in the Pharmaceutical Excipient Market:

  • Ashland Global Holdings
  • Croda International
  • BASF SE
  • Lubrizol Corporation
  • Evonik Industries AG
  • Associated British Foods
  • Roquette Feres
  • Archer Daniels Midland Company
  • DuPont
  • Avantor Performance Materials, Inc.
  • The Dow Chemical Company
  • FMC Corporation
  • Evonik Industries
  • Lubrizol Corporation
  • Roquette
  • Colorcon, Inc.

Key Segments:

By Type:

  • Organic Chemicals
  • Oleochemicals
    • Fatty Alcohols
    • Mineral Stearates
    • Glycerin
    • Other Oleochemicals
  • Carbohydrates
    • Sugars
      • Actual Sugars
      • Sugar Alcohols
      • Artificial Sweeteners
    • Cellulose
      • Microcrystalline cellulose
      • Cellulose ethers
      • Carboxymethyl cellulose (CMC) and croscarmellose sodium
      • Cellulose esters
    • Starch
      • Modified Starch
      • Dried Starch
      • Converted Starch
  • Petrochemicals
    • Glycols
    • Povidones
    • Mineral Hydrocarbons
    • Acrylic Polymers
    • Other Petrochemical Excipients
  • Proteins
  • Other Organic Chemicals
  • Artificial
  • Calcium Phosphate
  • Metal Oxides
  • Halites
  • Calcium Carbonate
  • Calcium Sulphate
  • Other Artificial Chemicals
  • Other Chemicals

By Technique:

  • Fillers & Diluents
  • Suspending & Viscosity
  • Coating
  • Binders
  • Flavoring & Sweeteners
  • Disintegrants
  • Colorants
  • Lubricants & Glidants
  • Preservatives
  • Emulsifying

By Formulation:

  • Oral Formulations
  • Tablets
  • Capsules
    • Hard-gelatin Capsules
    • Soft-gelatin Capsules
  • Liquid Formulations
  • Other Oral Formulations
  • Topical Formulations
  • Parenteral Formulations
  • Other Formulations

By Application:

  • Taste Masking
  • Stabilizers
  • Modified-Release
  • Solubility & Bioavailability Enhancement
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

The global clinical information system market is set for remarkable growth, with projections indicating a Compound Annual Growth Rate (CAGR) of 8% between 2022 and 2032. This surge in expansion is fueled by a convergence of factors propelling innovation and transformation within the healthcare sector.

A significant catalyst driving this growth is the widespread adoption of Electronic Health Records (EHRs), which serves as a cornerstone in advancing the clinical information system industry. With healthcare providers increasingly embracing digitization, the integration of EHRs has become integral in optimizing patient care, streamlining operational processes, and facilitating data-informed decision-making.

Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-1018

Moreover, the escalating prevalence of chronic diseases globally further accelerates the momentum of this industry. The imperative need for sophisticated tools and systems to manage and treat chronic conditions effectively has surged the demand for advanced clinical information systems. These systems not only ensure seamless management of patient data but also enable personalized and value-based treatment methodologies.

"EHRs play a pivotal role in enhancing the quality and efficiency of healthcare delivery," says FMI. "They provide clinicians with real-time access to patient data, foster communication among healthcare providers, and mitigate medical errors."

The rising demand for value-based care also serves as a significant growth driver for the clinical information system industry. As healthcare shifts towards a model emphasizing high-quality care at reduced costs, clinical information systems emerge as critical enablers by facilitating real-time data access, seamless communication, and automation of administrative tasks.

With the increasing adoption of EHRs, the prevalence of chronic diseases, and the surge in demand for value-based care, the clinical information system industry is poised for sustained growth in the foreseeable future.

Key Takeaways from the "Clinical Information System Market by 2022 to 2032" report by Future Market Insights:

  • The global clinical information system industry is expected to grow at a CAGR of 8% from 2022 to 2032.
  • The integrated clinical decision support (CDSS) segment is expected to record the highest growth rate during the forecast period, due to the increasing demand for CDSS solutions to improve clinical decision-making and patient care.
  • The on-premises delivery mode segment is expected to account for the largest share of the market in 2022, but the cloud-based delivery mode segment is expected to grow at a faster rate during the forecast period.
  • The North America region is expected to remain the dominant market for clinical information systems throughout the forecast period, due to the presence of a large number of healthcare organizations and the high adoption of clinical information systems in the region.
  • The Asia Pacific region is expected to witness the fastest growth in the clinical information system market during the forecast period, due to the rising demand for clinical information systems from emerging economies such as China and India.

Some of the key factors driving the growth of the clinical information system market include:

  • Increasing prevalence of chronic diseases
  • Rising investments in healthcare IT
  • Government initiatives to promote the use of electronic health records (EHRs)
  • Technological advancements such as cloud computing, artificial intelligence (AI), and machine learning (ML)

The clinical information system industry is highly competitive, with a number of established players such as Cerner, Epic, and MEDITECH. However, there is also a growing number of new entrants in the market, such as Allscripts and eClinicalWorks.

Overall, the clinical information system market is expected to witness significant growth in the coming years, driven by a number of factors such as the increasing prevalence of chronic diseases, rising investments in healthcare IT, and government initiatives to promote the use of EHRs.

Some of the key players in the clinical information system market include:

  • Cerner Corporation
  • Epic Systems Corporation
  • McKesson Corporation
  • Allscripts Healthcare, LLC
  • MEDITECH Corporation
  • NextGen Healthcare, Inc.

The Segmentation of the Clinical Information System (CIS) Market Some Common Segmentation Criteria Include:

By End Use:

  • Hospital
  • Outpatient Hospital
  • Business Office

By Type:

  • Hardware
  • Software
  • Services

By Delivery Mode:

  • On-Premises
  • Cloud-Based

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe
Pages: «« « ... 9 10 11 12 13 ... » »»